每经头条（nbdtoutiao）——伤亡180万人！俄乌冲突四周年，陷入谈判死局、战场僵局、经济困局！谁 为战争买单 （记者 张明双） 每经AI快讯，艾迪药业2月24日晚间发布2025年度业绩快报，营业收入约7.21亿元，同比增加72.49%； 归属于上市公司股东的净利润亏损1973.37万元。 ...

Core Viewpoint - The company Koyuan Pharmaceutical (301281) has significantly revised its net profit forecast for 2025, expecting a decline of 70% to 80% compared to the previous year due to a lawsuit involving its subsidiary, Lino Pharmaceutical. Financial Performance - The revised forecast for net profit attributable to shareholders is between 12.09 million yuan and 18.13 million yuan, down from the previous estimate of 27.20 million yuan to 39.29 million yuan, which represented a decline of 35% to 55% year-on-year [1][2] - The non-recurring net profit remains unchanged at between 20.12 million yuan and 29.06 million yuan [1][2] Legal Issues - Lino Pharmaceutical received a civil judgment from the Jiangsu Province court, requiring it to pay 16.11 million yuan in compensation related to a contract dispute with Jiangsu Saibang Pharmaceutical [1][3] - This judgment is considered an event that requires adjustment to the financial statements, leading to an increase in non-operating expenses by approximately 16.11 million yuan, which will reduce the net profit attributable to shareholders [3] Operational Challenges - Due to the contract dispute, one of Lino Pharmaceutical's bank accounts has been frozen, with 57 million yuan in funds affected, representing 4.19% of the company's latest audited net assets attributable to shareholders [6] - Koyuan Pharmaceutical primarily engages in the research, production, and sales of chemical raw materials and their formulations, along with intermediate business [6] Market Activity - In November 2025, Koyuan Pharmaceutical announced the termination of its acquisition of Hongjitang, initially planned to purchase 99.42% of the shares from Lino Investment Holding Group and others [6] - The decision to terminate the acquisition was made after careful consideration of changes in the overall market environment, aiming to protect the long-term interests of all shareholders [6]

Core Insights - Fosun International has continued its strong growth momentum in 2026, particularly in sectors such as cultural tourism, consumer goods, and innovative pharmaceuticals, driven by the commercialization of innovative results and deepening global operations [1][2] Group 1: Cultural Tourism and Consumer Growth - During the Spring Festival, Fosun's cultural tourism segment showed robust growth, with Shanghai Yuyuan Mall receiving nearly 1.2 million visitors, a year-on-year increase of over 20% [1] - Club Med's five domestic resorts achieved an average occupancy rate of 90% during the Spring Festival core holiday period [1] - Atlantis Sanya reported a total revenue of 124 million yuan during the Spring Festival holiday, marking a 20% year-on-year growth and setting a record for the best performance during the Spring Festival [1] Group 2: Innovative Pharmaceuticals - Fosun's innovative pharmaceutical sector has seen significant advancements, with its subsidiary, Fuhong Hanlin, receiving clinical trial approvals for HLX15-SC from both the Chinese National Medical Products Administration and the FDA [2] - HLX15, a biosimilar to Daratumumab, has a projected global sales potential of approximately 12.88 billion yuan in 2024 [2] - In 2025, Fosun Pharma's innovative drug revenue exceeded 6.7 billion yuan, reflecting an 18.09% year-on-year increase, with innovative drugs accounting for 32% of the pharmaceutical segment [3] Group 3: Strategic Collaborations and Future Growth - Fosun Pharma's subsidiary, Yaoyou Pharmaceutical, signed a global exclusive licensing agreement with Pfizer for the oral GLP-1 drug YP05002, with potential total payments exceeding 2 billion dollars [4] - A strategic partnership with Clavis Bio aims to develop innovative therapies based on cutting-edge targets, with potential payments up to 7.25 billion dollars [4] - The innovative drug growth is further supported by the successful global development of core products from Fuhong Hanlin, which saw a stock price increase of approximately 150% in 2025 [4] Group 4: Globalization and Financial Performance - Fosun's overseas business revenue reached a historic high of 53% in the first half of 2025, reflecting its deep industry layout and operations in over 40 countries [6] - The overseas revenue from Fosun Pharma's innovative drugs grew by 184%, surpassing 10 billion yuan [7] - The financial health of Fosun is reinforced by strategic asset divestitures and a reduction in debt costs, with total debt to total capital ratio at 53% as of mid-2025 [8][9]

Core Insights - The company reported a total operating revenue of 721 million yuan for the fiscal year 2025, representing a year-on-year increase of 72.49% [1] - The company achieved an operating profit of 47.746 million yuan, marking a turnaround from loss to profit [1] - The total profit amounted to 24.3042 million yuan, also indicating a shift from loss to profit [1] - The net profit attributable to the parent company's owners was -19.7337 million yuan, with the loss margin decreasing by 86.02% compared to the previous year [2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -20.9272 million yuan, with the loss margin decreasing by 85.90% year-on-year [1][2] Financial Performance - The company's total assets at the end of the reporting period were 1.916 billion yuan, an increase of 2.50% from the beginning of the period [1] - The equity attributable to the parent company's owners was 964 million yuan, a decrease of 1.67% from the beginning of the period [1] Key Drivers of Performance - The increase in revenue was primarily driven by higher income from innovative HIV drugs and the consolidation of Nanda Pharmaceutical's operational data, resulting in a gross profit increase of approximately 255 million yuan [2] - Sales expenses rose by approximately 92 million yuan due to increased efforts in new drug promotion and the consolidation of Nanda Pharmaceutical's operational data [2] - Asset impairment losses decreased by approximately 48 million yuan as market expansion and expectations stabilized [2]

Core Viewpoint - Eddie Pharmaceuticals reported a total revenue of 721 million yuan for the fiscal year 2025, representing a year-on-year increase of 72.49%. However, the company incurred a net loss of 19.73 million yuan, an improvement from a loss of 141 million yuan in the same period last year [1]. Group 1: Financial Performance - The increase in total revenue is attributed to higher income from innovative anti-HIV drugs and the operational data from the merger with Nanda Pharmaceuticals [1]. - The gross profit from core business increased by approximately 255 million yuan compared to the same period last year [1]. - The net loss decreased significantly from 141 million yuan to 19.73 million yuan, indicating improved financial health [1]. Group 2: Expenses and Costs - Sales expenses rose by approximately 92 million yuan compared to the previous year due to increased efforts in new drug promotion and the merger with Nanda Pharmaceuticals [1]. - Asset impairment losses decreased by about 48 million yuan compared to the same period last year, reflecting a stabilization in market expansion and expectations [1].

Core Viewpoint - The approval of the active pharmaceutical ingredient (API) for Minaprine Hydrochloride by the National Medical Products Administration indicates that the product meets national drug approval technical standards, allowing for production and sales in the domestic market, which will enhance the company's market competitiveness and positively impact future development [1] Group 1 - The company’s wholly-owned subsidiary, Jiangsu Weichida Pharmaceutical Co., Ltd., received the approval notice for the API Minaprine Hydrochloride [1] - Minaprine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) developed by Pierre Fabre for the treatment of major depressive disorder [1] - The approval will help the company advance the integration of its product supply chain, optimize resource allocation, and improve its industry layout [1]

Core Viewpoint - The approval of the active pharmaceutical ingredient (API) for Minaprine Hydrochloride by the National Medical Products Administration (NMPA) signifies a positive development for the company, enhancing its market competitiveness and resource allocation [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Jiangsu Weichida Pharmaceutical Co., Ltd., received the approval notice for the listing application of Minaprine Hydrochloride [1] - Minaprine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) developed by Pierre Fabre, intended for the treatment of major depressive disorder [1] - The approval indicates that the API meets national pharmaceutical approval technical standards, allowing for production and sales in the domestic market [1] Group 2: Strategic Implications - The approval will assist the company in advancing the industrial chain integration of related products, optimizing resource allocation and industrial layout [1] - This development is expected to enhance the company's product market competitiveness and positively impact future growth [1] - The matter is not anticipated to have a significant impact on the company's current operating performance [1]

Core Viewpoint - The company Guoyao Modern (600420.SH) announced that its wholly-owned subsidiary, Jiangsu Weichida Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the active pharmaceutical ingredient, Minaprine Hydrochloride [1] Group 1 - The approved drug, Minaprine Hydrochloride, is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) developed by Pierre Fabre, intended for the treatment of major depressive disorder [1]

Core Viewpoint - The approval of the active pharmaceutical ingredient, Mianaprine Hydrochloride, by the National Medical Products Administration is a significant milestone for the company, enhancing its integrated supply chain capabilities while facing sales uncertainties due to various factors [1] Group 1: Regulatory Approval - The company's wholly-owned subsidiary, China National Pharmaceutical Group Jiangsu Weichida, received the approval notice for the listing application of Mianaprine Hydrochloride [1] - The approval is crucial for the treatment of severe depression, with a global consumption of 3,639.95 kg in 2023 [1] Group 2: Research and Development - The application for the active pharmaceutical ingredient was submitted in October 2024 and passed the review in February 2026 [1] - The total R&D investment for this project amounted to approximately 7.1823 million yuan [1] Group 3: Market Implications - The approval supports the company's efforts to advance its integrated supply chain [1] - However, sales of the product may be influenced by multiple factors, leading to uncertainties in market performance [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has entered into an exclusive licensing agreement with GSK for two siRNA product pipelines, which will enhance its global collaboration efforts [4][5] - The revenue forecast for the company is maintained at 143 million, 169 million, and 201 million yuan for 2025, 2026, and 2027 respectively, while the net profit estimates have been revised downwards to -257 million, -208 million, and -199 million yuan for the same years [4][5] - The current stock price corresponds to a price-to-sales ratio (P/S) of 59.3, 50.2, and 42.1 for 2025, 2026, and 2027 respectively, indicating a long-term competitive outlook due to the company's focus on small nucleic acid pipeline development [4][5] Financial Summary - The company reported a revenue of 114 million yuan in 2023, with a year-on-year growth of 34.8%, and is projected to grow to 201 million yuan by 2027 [8] - The net profit for 2023 was -329 million yuan, with an expected improvement to -199 million yuan by 2027 [8] - The gross margin is expected to improve from 29.0% in 2023 to 34.2% in 2027, while the net margin is projected to improve from -287.9% to -99.2% over the same period [8]